• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vera Therapeutics, Inc. - Class A Common Stock (NQ: VERA )

    42.29 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 42.29
    Bid (Size) 20.01 (1)
    Ask (Size) 62.79 (1)
    Prev. Close 42.29
    Today's Range 42.29 - 42.29
    52wk Range 14.20 - 51.61
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    N/A
    N/A
    1 Month
    -14.65%
    -14.65%
    3 Month
    -1.26%
    -1.26%
    6 Month
    +21.07%
    +21.07%
    1 Year
    +170.92%
    +170.92%

    More News

    Read More
    Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics to Participate at Upcoming Investor Conferences
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
    Via Benzinga
    PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug
    Via Investor's Business Daily
    Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Vera Therapeutics to Participate at September Investor Conferences
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024
    Via InvestorPlace
    Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.